Antimicrobial Stewardship with and without Infectious Diseases Specialist Services to Improve Quality-of-Care in Secondary and Tertiary Care Hospitals in Germany : Study Protocol of the ID ROLL OUT Study
© 2021. The Author(s)..
BACKGROUND: Antimicrobial stewardship (AMS) programs aim to secure the rational prescription of antibiotics through implementing department- or hospital-level activities. Infectious disease (ID) specialists improve the quality of care and outcomes in infection patients predominantly by individual consultations and patient-level interventions. While hospital AMS programs are established to various extents in Germany, ID specialist services are rarely available in this country. In the ID ROLL OUT study, we will implement and evaluate hospital-level AMS tools with and without ID specialist services in secondary and tertiary care hospitals. We aim to identify means to comprehensively and sustainably improve the quality of care of patients with infectious diseases.
METHODS: This project is a clustered, two-armed intervention study, which will be conducted in ten secondary and tertiary (non-university) care hospitals in Germany. The intervention groups are stratified by key characteristics of the hospitals. We will compare two interventional strategies: implementation of AMS teams and implementation of AMS teams combined with the activities of ID specialists (AMS + IDS).
PLANNED OUTCOMES: The primary outcome is the quality of care as measured in changes in a Staphylococcus aureus bacteremia (SAB) score (as an indicator of difficult-to-treat infections) and a community-acquired pneumonia (CAP) score (as an indicator of common infections) compared to a baseline pre-interventional period. Our secondary outcomes comprise patient- and hospital-level outcomes, such as the quality and frequency of antibiotic treatment, in-hospital mortality, duration of hospitalization, and C. difficile incidence (associated diarrhea episodes). The study may provide urgently needed key information for the aspired advancement of ID care in Germany.
TRIAL REGISTRATION: DRKS00023710 (registered on 9th April 2021).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Infectious diseases and therapy - 11(2022), 1 vom: 09. Feb., Seite 617-628 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zimmermann, Nicole [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibiotic resistance |
|---|
| Anmerkungen: |
Date Revised 16.02.2022 published: Print-Electronic DRKS: DRKS00023710 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40121-021-00552-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332899411 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332899411 | ||
| 003 | DE-627 | ||
| 005 | 20231225220527.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40121-021-00552-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332899411 | ||
| 035 | |a (NLM)34751941 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zimmermann, Nicole |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antimicrobial Stewardship with and without Infectious Diseases Specialist Services to Improve Quality-of-Care in Secondary and Tertiary Care Hospitals in Germany |b Study Protocol of the ID ROLL OUT Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a DRKS: DRKS00023710 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a BACKGROUND: Antimicrobial stewardship (AMS) programs aim to secure the rational prescription of antibiotics through implementing department- or hospital-level activities. Infectious disease (ID) specialists improve the quality of care and outcomes in infection patients predominantly by individual consultations and patient-level interventions. While hospital AMS programs are established to various extents in Germany, ID specialist services are rarely available in this country. In the ID ROLL OUT study, we will implement and evaluate hospital-level AMS tools with and without ID specialist services in secondary and tertiary care hospitals. We aim to identify means to comprehensively and sustainably improve the quality of care of patients with infectious diseases | ||
| 520 | |a METHODS: This project is a clustered, two-armed intervention study, which will be conducted in ten secondary and tertiary (non-university) care hospitals in Germany. The intervention groups are stratified by key characteristics of the hospitals. We will compare two interventional strategies: implementation of AMS teams and implementation of AMS teams combined with the activities of ID specialists (AMS + IDS) | ||
| 520 | |a PLANNED OUTCOMES: The primary outcome is the quality of care as measured in changes in a Staphylococcus aureus bacteremia (SAB) score (as an indicator of difficult-to-treat infections) and a community-acquired pneumonia (CAP) score (as an indicator of common infections) compared to a baseline pre-interventional period. Our secondary outcomes comprise patient- and hospital-level outcomes, such as the quality and frequency of antibiotic treatment, in-hospital mortality, duration of hospitalization, and C. difficile incidence (associated diarrhea episodes). The study may provide urgently needed key information for the aspired advancement of ID care in Germany | ||
| 520 | |a TRIAL REGISTRATION: DRKS00023710 (registered on 9th April 2021) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antibiotic resistance | |
| 650 | 4 | |a Antibiotic stewardship (ABS) | |
| 650 | 4 | |a Community-acquired pneumonia | |
| 650 | 4 | |a Consultation | |
| 650 | 4 | |a Infectious diseases specialist | |
| 650 | 4 | |a Staphylococcus aureus bacteremia | |
| 700 | 1 | |a Allen, Rebekka |e verfasserin |4 aut | |
| 700 | 1 | |a Fink, Geertje |e verfasserin |4 aut | |
| 700 | 1 | |a Först, Gesche |e verfasserin |4 aut | |
| 700 | 1 | |a Kern, Winfried V |e verfasserin |4 aut | |
| 700 | 1 | |a Farin-Glattacker, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Rieg, Siegbert |e verfasserin |4 aut | |
| 700 | 0 | |a ID ROLL OUT Study group |e verfasserin |4 aut | |
| 700 | 1 | |a Solzbach, U |e investigator |4 oth | |
| 700 | 1 | |a Friedrich, H |e investigator |4 oth | |
| 700 | 1 | |a van Uden, C |e investigator |4 oth | |
| 700 | 1 | |a Meyer, K |e investigator |4 oth | |
| 700 | 1 | |a Hebart, H |e investigator |4 oth | |
| 700 | 1 | |a Tremmel, T |e investigator |4 oth | |
| 700 | 1 | |a Bommer, M |e investigator |4 oth | |
| 700 | 1 | |a Busch, A |e investigator |4 oth | |
| 700 | 1 | |a Schmidt, A |e investigator |4 oth | |
| 700 | 1 | |a Polk, S |e investigator |4 oth | |
| 700 | 1 | |a La Rosée, P |e investigator |4 oth | |
| 700 | 1 | |a Geiser, M |e investigator |4 oth | |
| 700 | 1 | |a Mertins, S |e investigator |4 oth | |
| 700 | 1 | |a Schuhmacher, C |e investigator |4 oth | |
| 700 | 1 | |a Götz, M |e investigator |4 oth | |
| 700 | 1 | |a von Ameln-Mayerhofer, A A |e investigator |4 oth | |
| 700 | 1 | |a Khaleqi, F |e investigator |4 oth | |
| 700 | 1 | |a Winter, K |e investigator |4 oth | |
| 700 | 1 | |a Ritter, M |e investigator |4 oth | |
| 700 | 1 | |a Wagner, F |e investigator |4 oth | |
| 700 | 1 | |a Reinecke, S |e investigator |4 oth | |
| 700 | 1 | |a Haase, Sr Karin Johanna |e investigator |4 oth | |
| 700 | 1 | |a Horn, S |e investigator |4 oth | |
| 700 | 1 | |a Lindner, S |e investigator |4 oth | |
| 700 | 1 | |a Reistle, B |e investigator |4 oth | |
| 700 | 1 | |a Kollum, M |e investigator |4 oth | |
| 700 | 1 | |a Buchal, P |e investigator |4 oth | |
| 700 | 1 | |a Schmid, M |e investigator |4 oth | |
| 700 | 1 | |a Müller, S |e investigator |4 oth | |
| 700 | 1 | |a Sorichter, S |e investigator |4 oth | |
| 700 | 1 | |a Grüninger, R |e investigator |4 oth | |
| 700 | 1 | |a Wuwer, Y |e investigator |4 oth | |
| 700 | 1 | |a Niese, H |e investigator |4 oth | |
| 700 | 1 | |a Iber, T |e investigator |4 oth | |
| 700 | 1 | |a Hohenstein, D |e investigator |4 oth | |
| 700 | 1 | |a Witten-Stephan, U |e investigator |4 oth | |
| 700 | 1 | |a Wirth, D |e investigator |4 oth | |
| 700 | 1 | |a Steib-Bauert, M |e investigator |4 oth | |
| 700 | 1 | |a Kaier, K |e investigator |4 oth | |
| 700 | 1 | |a Sehlbrede, M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d 2012 |g 11(2022), 1 vom: 09. Feb., Seite 617-628 |w (DE-627)NLM240483693 |x 2193-8229 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:1 |g day:09 |g month:02 |g pages:617-628 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40121-021-00552-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 1 |b 09 |c 02 |h 617-628 | ||